ClinicalTrials.gg
CompletedNCT05258747Updated Oct 3, 2024Results posted

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

A Phase 1 interventional study of Olaparib tablets, 150 mg and Lynparza® (olaparib) tablets 150 mg in Ovarian Cancer and Breast Cancer, sponsored by Sandoz. Completed at 1 site in India. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
39th of 69
70 · median 97
Started
2022
with 2 others
Phase 1
15 of 69
2 open now
Registered
56th of 69
by date

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 39th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 1, and was the 56th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.

Read the detailed description

This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.

Patients will be enrolled after providing written informed consent and treatments will be allocated to patient by carrying out randomization using statistical techniques.

Patients that are already on a stable dose of Lynparza® (olaparib) tablets and have met the eligibility criteria will be directly randomized for participation in the study.

After randomization patients will receive either test or reference product in a crossover manner based on the randomization schedule. Patients will receive the dose of 300 mg twice daily for 16 days in a crossover design.

In period-I (Day 1 to Day 8), patients will receive either Test product or Reference product for 8 days based on the randomization schedule.

In period-II (Day 9 to Day 16), patients will be switched to the other product for a second period of 8 days.

03

Conditions studied

  • Ovarian Cancer
  • Breast Cancer

Keywords

  • cancer of the ovaries,
  • female reproductive cancer,
  • ovarian carcinoma,
  • female breast cancer
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.

OR Maintenance Treatment of Recurrent Ovarian Cancer maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.

OR Advanced Germline BRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

OR Germline BRCA-mutated Human epidermal growth factor receptor 2 () -negative Breast Cancer treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the , adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.

  • Non-smoking, non-pregnant, non-lactating female patient ≥18 years of age with a (BMI) in the range of 18.50 to 30.00 kg/m\^2 (both inclusive).
  • Able to give written for participation in the trial and willing to adhere to protocol requirements.
  • Patient having an estimated survival of at least 3 months
  • Adequate organ and bone marrow function based upon the following laboratory criteria at the time of eligibility assessment prior to dosing in period 1
  • (ECOG) performance status of 0-2.
  • Women of non child bearing potential with documented evidence of hysterectomy / bilateral salpingectomy / bilateral oophorectomy at least 6 months prior to Medicinal Product (IMP) administration or for at least 12 consecutive months.

OR Women of child bearing potential must have negative pregnancy test at screening visit and before randomization and must agree to use an effective method of avoiding pregnancy (including oral, transdermal or implanted [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to IMP administration] sexual partner) for at least 4 weeks prior to IMP administration, during the study and up to 6 months after the last dose of IMP. Cessation of birth control after this point should be discussed with a responsible physician.

Exclusion criteria

Exclusion Criteria:

  • History of known to olaparib or its components which, in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.
  • Usage of strong and moderate inhibitors (e.g., cimetidine, ciprofloxacin, grapefruit juice) or strong and moderate CYP3A4 inducers (e.g., carbamazepine, phenytoin, St. John"s Wort, rifampicin) within 30 days prior to first dosing in Period 01.
  • Pregnant or lactating females.
  • History or presence of lactose, galactose, or fructose intolerance.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Other
    Olaparib tablets, 150 mg, then Lynparza® (olaparib) tablets 150 mg

    participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design

    Drug: Olaparib tablets, 150 mg · Drug: Lynparza® (olaparib) tablets 150 mg

  • Other
    Lynparza® (olaparib) tablets 150 mg, then Olaparib tablets, 150 mg

    participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design

    Drug: Olaparib tablets, 150 mg · Drug: Lynparza® (olaparib) tablets 150 mg

Interventions

  • DrugOlaparib tablets, 150 mg

    Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia

  • Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS)

    To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with Breast Cancer Gene (BRCA) mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.

    Time frame: Pre-dose (0.00 hr) on day 1,6,7,8,14,15 and 16 and Post-dose on day 8 and day 16

  2. Area Under the Plasma Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-t)ss)

    To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.

    Time frame: Pre-dose (0.00 hr) on day 1,6,7,8,14,15 and 16 and Post-dose on day 8 and day 16

Secondary outcomes

  1. Number of Serious Adverse Events

    To monitor the serious adverse events of patients and to assess safety of each of the two formulations.

    Time frame: up to Day 24

  2. Number of Adverse Events

    To monitor the adverse events of patients and to assess safety of each of the two formulations.

    Time frame: up to Day 24

07

Results

Posted Oct 3, 2024

Participant flow

First Period
Participant flow — First Period
MilestoneOlaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg
Started3535
Completed3535
Not completed00
Second Period
Participant flow — Second Period
MilestoneOlaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg
Started3535
Completed3435
Not completed10

Outcome measures

PrimaryMaximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS)

To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with Breast Cancer Gene (BRCA) mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.

Time frame:
Pre-dose (0.00 hr) on day 1,6,7,8,14,15 and 16 and Post-dose on day 8 and day 16
Reported as:
Mean · ng/mL
Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS)
ng/mLOlaparib Tablets, 150 mgLynparza® (Olaparib) Tablets 150 mg
Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS)10395.085 ± 3374.48009676.278 ± 2845.1708
PrimaryArea Under the Plasma Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-t)ss)

To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.

Time frame:
Pre-dose (0.00 hr) on day 1,6,7,8,14,15 and 16 and Post-dose on day 8 and day 16
Reported as:
Mean · hr*ng/mL
Area Under the Plasma Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-t)ss)
hr*ng/mLOlaparib Tablets, 150 mgLynparza® (Olaparib) Tablets 150 mg
Area Under the Plasma Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-t)ss)59480.137 ± 25073.701664104.218 ± 29492.0018
SecondaryNumber of Serious Adverse Events

To monitor the serious adverse events of patients and to assess safety of each of the two formulations.

Time frame:
up to Day 24
Reported as:
Number · Number of Serious Adverse Events
Number of Serious Adverse Events
Number of Serious Adverse EventsOlaparib Tablets, 150 mgLynparza® (Olaparib) Tablets 150 mg
Number of Serious Adverse Events01
SecondaryNumber of Adverse Events

To monitor the adverse events of patients and to assess safety of each of the two formulations.

Time frame:
up to Day 24
Reported as:
Number · Number of Adverse Events
Number of Adverse Events
Number of Adverse EventsOlaparib Tablets, 150 mgLynparza® (Olaparib) Tablets 150 mg
Number of Adverse Events4337

Adverse events

Collected over From signing informed consent form till end of the study safety assessments (24 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib Tablets, 150 mg0/70 (0%)0/70 (0%)19/70 (27.1%)
Lynparza® (Olaparib) Tablets 150 mg0/69 (0%)1/69 (1.4%)17/69 (24.6%)
Most frequent serious events
Most frequent serious events
EventOlaparib Tablets, 150 mgLynparza® (Olaparib) Tablets 150 mg
AstheniaGeneral disorders0/701/69
Most frequent other events
Most frequent other events
EventOlaparib Tablets, 150 mgLynparza® (Olaparib) Tablets 150 mg
AnaemiaBlood and lymphatic system disorders7/707/69
NauseaGastrointestinal disorders6/704/69
White blood cell count decreasedInvestigations2/704/69
AstheniaGeneral disorders4/702/69

Baseline characteristics

Age, Continuous
Age, Continuous(years)Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mgTotal
Mean47.77 ± 8.97750.74 ± 10.59049.26 ± 9.859
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mgTotal
Female353570
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mgTotal
Hispanic or Latino000
Not Hispanic or Latino353570
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mgTotal
American Indian or Alaska Native000
Asian353570
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mgTotal
India353570
BMI
BMI(Kg/m^2)Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mgLynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mgTotal
Mean25.27 ± 3.48025.62 ± 3.44425.44 ± 3.441
08

Study locations

1 site
  • Sandoz Investigative Site
    Vijayawada, Andhra Pradesh 520002, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Oct 2022, 6 months.

Results were first posted in Oct 2024, 1 year 11 months after primary completion.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 6 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Feb 28, 2022
StartActual
Apr 7, 2022
Primary completionActual
Oct 20, 2022
CompletionActual
Oct 20, 2022
Results first posted
Oct 3, 2024
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05258747
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Feb 28, 2022
Start date
Apr 7, 2022
Primary completion
Oct 20, 2022
Completion
Oct 20, 2022
Results posted
Oct 3, 2024
Last update
Oct 3, 2024

Study contacts

Sandoz
study director · Sandoz

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion